Clinical Trial

Platelet Sub-study of the Neomindset Trial

Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated April 8, 2025 (before its estimated May 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
The general purpose of the Neomindset trial is to evaluate the non-inferiority hypothesis for ischemic events and the superiority hypothesis for bleeding events resulting from platelet P2Y12 receptor inhibitors given as monotherapy in comparison with conventional dual antiplatelet therapy in acute coronary syndrome patients treated with percutaneous coronary intervention. The platelet sub-study will be conducted at the Hospital Israelita Albert Einstein. This sub-study will recruit randomized patients from the Neomindset trial to evaluate platelet function after at least 30 days of study treatment with either P2Y12 inhibitor monotherapy or dual antiplatelet therapy.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-03-02.
Status change: Recruiting → Active, Not Recruiting 2025-04-04
Trial Details
NCT Number NCT05767723
Lead Sponsor Hospital Israelita Albert Einstein
Conditions Acute Coronary Syndrome
Enrollment 48 participants
Start Date 2023-02-06
Primary Completion 2025-05-30 (estimated)
Study Completion 2025-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-04-08